Unlock the code of MHC II-enabled Cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Major Histocompatibility Complex class II (MHC II) molecules present tumor antigens to CD4+ T cells, initiating anti-cancer immunity.
• Recent findings show MHC II expression on atypical antigen-presenting cells (APCs), increasing interest in MHC II-targeted immunotherapies.

Purpose of the Study:

• To review MHC II-mediated immunoregulatory networks in professional and atypical APCs.
• To explore MHC II's potential as a biomarker and therapeutic target in cancer.
• To discuss predictive models for MHC II-antigen interactions in precision oncology.

Main Methods:

• Literature review of MHC II function in anti-cancer immunity.
• Analysis of emerging immunotherapies targeting MHC II expression.
• Exploration of predictive models for MHC II-antigen interactions.

Main Results:

• MHC II expression on atypical APCs offers new immunotherapy avenues.
• Therapies enhancing MHC II expression show promise for cold tumors.
• MHC II-guided vaccines, ICB, and combination therapies demonstrate clinical efficacy.

Conclusions:

• Understanding MHC II networks is crucial for optimizing immunotherapy.
• Targeting MHC II can address tumor heterogeneity and improve tailored treatments.
• Further research into MHC II-antigen interactions will advance precision oncology.